Cargando…
Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
BACKGROUND: Fistula and intraabdominal fistula are common complications of Crohn’s disease (CD), but complex rectal fistula with abscess formation is rare. Tumor necrosis factor antagonists combined with percutaneous drainage or surgical intervention is optimal treatment for fistulizing CD with intr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856844/ https://www.ncbi.nlm.nih.gov/pubmed/33584075 http://dx.doi.org/10.3748/wjg.v27.i5.442 |
_version_ | 1783646324633108480 |
---|---|
author | Yeh, Heng Kuo, Chia-Jung Wu, Ren-Chin Chen, Chien-Ming Tsai, Wen-Sy Su, Ming-Yao Chiu, Cheng-Tang Le, Puo-Hsien |
author_facet | Yeh, Heng Kuo, Chia-Jung Wu, Ren-Chin Chen, Chien-Ming Tsai, Wen-Sy Su, Ming-Yao Chiu, Cheng-Tang Le, Puo-Hsien |
author_sort | Yeh, Heng |
collection | PubMed |
description | BACKGROUND: Fistula and intraabdominal fistula are common complications of Crohn’s disease (CD), but complex rectal fistula with abscess formation is rare. Tumor necrosis factor antagonists combined with percutaneous drainage or surgical intervention is optimal treatment for fistulizing CD with intraabdominal abscess. There is no study show the efficacy of vedolizumab in such complicated condition. CASE SUMMARY: A 47-year-old man has decompensated liver cirrhosis, child B. He suffered from abdominal pain, bloody diarrhea, fever, and body weight loss. CD with rectoprostatic fistula, rectopresacral fistula, pre-sacral abscess and cyto-megalovirus (CMV) infection were noted. He received antibiotics, anti-viral therapy, transverse colostomy and vedolizumab treatment. Six months later, he had deep remission and complete fistula tracts closure. CONCLUSION: Early vedolizumab and stool diversion are effective and safe in treating CD with complex rectal fistula with abscess formation. |
format | Online Article Text |
id | pubmed-7856844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-78568442021-02-12 Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report Yeh, Heng Kuo, Chia-Jung Wu, Ren-Chin Chen, Chien-Ming Tsai, Wen-Sy Su, Ming-Yao Chiu, Cheng-Tang Le, Puo-Hsien World J Gastroenterol Case Report BACKGROUND: Fistula and intraabdominal fistula are common complications of Crohn’s disease (CD), but complex rectal fistula with abscess formation is rare. Tumor necrosis factor antagonists combined with percutaneous drainage or surgical intervention is optimal treatment for fistulizing CD with intraabdominal abscess. There is no study show the efficacy of vedolizumab in such complicated condition. CASE SUMMARY: A 47-year-old man has decompensated liver cirrhosis, child B. He suffered from abdominal pain, bloody diarrhea, fever, and body weight loss. CD with rectoprostatic fistula, rectopresacral fistula, pre-sacral abscess and cyto-megalovirus (CMV) infection were noted. He received antibiotics, anti-viral therapy, transverse colostomy and vedolizumab treatment. Six months later, he had deep remission and complete fistula tracts closure. CONCLUSION: Early vedolizumab and stool diversion are effective and safe in treating CD with complex rectal fistula with abscess formation. Baishideng Publishing Group Inc 2021-02-07 2021-02-07 /pmc/articles/PMC7856844/ /pubmed/33584075 http://dx.doi.org/10.3748/wjg.v27.i5.442 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Case Report Yeh, Heng Kuo, Chia-Jung Wu, Ren-Chin Chen, Chien-Ming Tsai, Wen-Sy Su, Ming-Yao Chiu, Cheng-Tang Le, Puo-Hsien Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title | Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title_full | Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title_fullStr | Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title_full_unstemmed | Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title_short | Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report |
title_sort | vedolizumab in crohn’s disease with rectal fistulas and presacral abscess: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856844/ https://www.ncbi.nlm.nih.gov/pubmed/33584075 http://dx.doi.org/10.3748/wjg.v27.i5.442 |
work_keys_str_mv | AT yehheng vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT kuochiajung vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT wurenchin vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT chenchienming vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT tsaiwensy vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT sumingyao vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT chiuchengtang vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport AT lepuohsien vedolizumabincrohnsdiseasewithrectalfistulasandpresacralabscessacasereport |